Laborate Pharmaceuticals India Limited

laborate.com

Indian based Global Pharmaceuticals company with one of the fastest growing rate in the Industry! Laborate was started in 1985 with the mission to help this world specially the poor with better healthcare facility. Our team is working hard in over 35 countries around the globe to serve the mission with excellence. Laborate is certified y World Health Organisation (WHO) and Joint accreditation System of Australia and New Zealand. We take pride on our self for providing excellent healthcare service at affordable price!

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

EAGLE PHARMACEUTICALS AGREED TO ACQUIRE ACACIA PHARMA GROUP PLC

Eagle Pharmaceuticals, Inc. | March 29, 2022

news image

Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...

Read More

RESEARCH

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

news image

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More

BUSINESS INSIGHTS

BRUKER ACQUIRES OPTIMAL COMPANIES FOR PHARMA PAT SOFTWARE AND BIOPHARMA MANUFACTURING AUTOMATION EXPERTISE AND TECHNOLOGIES

Bruker Corporation | April 06, 2022

news image

Bruker Corporation announced the acquisition of Optimal Industrial Automation and Technologies, a leader in pharma and biopharma process analytical technology pharma manufacturing automation and Quality Assurance (QA) software and systems integration, based in the United Kingdom. The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies. Financial details of the acquisi...

Read More

BUSINESS INSIGHTS

ANKURA LAUNCHES PHARMACEUTICAL DATA INTEGRITY SOLUTION

Ankura | March 09, 2022

news image

Ankura Consulting, LLC a leading global expert services and advisory firm announced the expansion of its Pharmaceutical and Biopharma Regulatory Compliance offering with the addition of a Pharmaceutical Data Integrity solution within the Data and Technology practice, bolstering its comprehensive client advisory capabilities. With this solution, Ankura has enhanced its team of experts to support pharmaceutical clients' compliance with the Data Integrity guidelines of multiple r...

Read More
news image

PHARMACY MARKET

EAGLE PHARMACEUTICALS AGREED TO ACQUIRE ACACIA PHARMA GROUP PLC

Eagle Pharmaceuticals, Inc. | March 29, 2022

Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...

Read More
news image

RESEARCH

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More
news image

BUSINESS INSIGHTS

BRUKER ACQUIRES OPTIMAL COMPANIES FOR PHARMA PAT SOFTWARE AND BIOPHARMA MANUFACTURING AUTOMATION EXPERTISE AND TECHNOLOGIES

Bruker Corporation | April 06, 2022

Bruker Corporation announced the acquisition of Optimal Industrial Automation and Technologies, a leader in pharma and biopharma process analytical technology pharma manufacturing automation and Quality Assurance (QA) software and systems integration, based in the United Kingdom. The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies. Financial details of the acquisi...

Read More
news image

BUSINESS INSIGHTS

ANKURA LAUNCHES PHARMACEUTICAL DATA INTEGRITY SOLUTION

Ankura | March 09, 2022

Ankura Consulting, LLC a leading global expert services and advisory firm announced the expansion of its Pharmaceutical and Biopharma Regulatory Compliance offering with the addition of a Pharmaceutical Data Integrity solution within the Data and Technology practice, bolstering its comprehensive client advisory capabilities. With this solution, Ankura has enhanced its team of experts to support pharmaceutical clients' compliance with the Data Integrity guidelines of multiple r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us